{
    "clinical_study": {
        "@rank": "14798", 
        "arm_group": {
            "arm_group_label": "plerixafor treated patients", 
            "description": "lymphoma and myeloma patients"
        }, 
        "brief_summary": {
            "textblock": "Plerixafor is a new CXCR4 inhibitor that is able to improve peripheral blood stem cell\n      (PBSC) mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). The\n      'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + G-CSF may\n      be more efficient and cost-effective, but the timing of administration and criteria for\n      patient selection are still under investigation. We collected the data of lymphoma and\n      myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy +\n      G-CSF. The decision of adding plerixafor was based on PB CD34+ cells at the time of\n      hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt,\n      according to the attending physician choice. The primary endpoint was the assessment of the\n      rate of patients who were able to collect >=2 x 10^6 CD34+/kg."
        }, 
        "brief_title": "Prospective Observational Study on Plerixafor After Chemotherapy", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Lymphoma", 
            "Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "Plerixafor is a new CXCR4 inhibitor that is able to improve peripheral blood stem cell\n      (PBSC) mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). The\n      'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + G-CSF may\n      be more efficient and cost-effective, but the timing of administration and criteria for\n      patient selection are still under investigation. We collected the data of lymphoma and\n      myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy +\n      G-CSF. The decision of adding plerixafor was based on PB CD34+ cells at the time of\n      hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt,\n      according to the attending physician choice. The primary endpoint was the assessment of the\n      rate of patients who were able to collect >=2 x 10^6 CD34+/kg. Secondary endpoint was the\n      assessment of the rate of patients collecting > 4 x 10^6 CD34+/kg and the median number of\n      apheresis to reach the target."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery\n             after chemotherapy and G-CSF\n\n        Exclusion Criteria:\n\n          -  patients treated only with G-CSF and plerixafor without chemotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after\n        chemotherapy and G-CSF"
            }
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700608", 
            "org_study_id": "011012"
        }, 
        "intervention": {
            "arm_group_label": "plerixafor treated patients", 
            "description": "plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy", 
            "intervention_name": "plerixafor", 
            "intervention_type": "Drug", 
            "other_name": "Mozobil"
        }, 
        "intervention_browse": {
            "mesh_term": "JM 3100"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 2, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milan", 
                    "country": "Italy", 
                    "zip": "20133"
                }, 
                "name": "Fondazione IRCCS Istituto Nazionale dei Tumori"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Observational Study on Plerixafor After Chemotherapy", 
        "other_outcome": {
            "measure": "To determine the median number of apheresis to reach >= 2-4 x 10^6 CD34+/kg", 
            "safety_issue": "No", 
            "time_frame": "From day 1 to day 25 after mobilizing chemotherapy"
        }, 
        "overall_official": {
            "affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori", 
            "last_name": "Paolo Corradini, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of patients who were able to collect >= 2 x 10^6 CD34+/kg", 
            "safety_issue": "No", 
            "time_frame": "From day 1 to day 25 after mobilizing chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700608"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
            "investigator_full_name": "Paolo Corradini", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients who were able to collect > 4 x 10^6 CD34+/kg.", 
            "safety_issue": "No", 
            "time_frame": "From day 1 to day 25 after mobilizing chemotherapy"
        }, 
        "source": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}